SCHEMBL466010

SCHEMBL466010

COC1=C[CH]CC=C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318359 0.84
SCHEMBL634177 0.78
SCHEMBL4019693 0.74
SCHEMBL16540752 0.73
SCHEMBL16915161 0.73
SCHEMBL7046785 0.73
SCHEMBL6225701 0.72
SCHEMBL13644461 0.70
SCHEMBL4771993 0.70 MPO (0.32)
SCHEMBL4807473 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2984186-A1 METHOD OF CONVERTING LIGNIN AND USES THEREOF Suganit Systems, Inc. (US) 2016-02-17 EP claimed
WO-2015184260-A2 METHODS FOR TREATING MENDELIAN DISORDERS OF THE EPIGENETIC MACHINERY THE JOHNS HOPKINS UNIVERSITY (US) 2015-12-03 WO claimed
WO-2014143657-A1 METHOD OF CONVERTING LIGNIN AND USES THEREOF SUGANIT SYSTEMS, INC. (US) 2014-09-18 WO claimed
EP-4153203-A1 COMPOSITIONS AND COMBINATIONS FOR SUBJECTS SUFFERING FROM ENDOMETRIOSIS Gynov (FR) 2023-03-29 EP disclosed
EP-3996729-A1 COMPOSITION FOR THE TREATMENT OF EMOTIONAL DISORDERS Mousset, Pierre-Yves (FR) 2022-05-18 EP disclosed
WO-2021240225-A1 IMMUNITY BOOSTER PRODUCT FOR PATIENTS OF COVID-19 NATUREVIVE IINNOVATION PRIVATE LIMITED (IN) 2021-12-02 WO disclosed
EP-3897652-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2021-10-27 EP disclosed
WO-2021005310-A1 COMPOSITION FOR THE TREATMENT OF EMOTIONAL DISORDERS MOUSSET PIERRE YVES (FR) 2021-01-14 WO disclosed
WO-2020132269-A1 SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS KSQ Therapeutics, Inc. (US) 2020-06-25 WO disclosed
EP-3110253-A1 SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL Emekatech, LLC (US) 2017-01-04 EP disclosed
WO-2016123520-A2 NOVEL PROCESS FOR PRODUCING VALUE-ADDED LIGNIN-BASED CHEMICALS FROM ALKALINE EFFLUENT OF CHEMICAL TREATMENT OF LIGNOCELLULOSIC BIOMASS WASHINGTON STATE UNIVERSITY (US) 2016-08-04 WO disclosed
EP-2318487-A2 MICROWAVE TORREFACTION OF BIOMASS University of York (GB) 2011-05-11 EP disclosed
WO-2010029562-A1 BIOACTIVE COMPOSITION FOR THE TREATMENT OF THE HIV/AIDS, METHOD FOR MANUFACTURING AND USING THE SAME SHUKLA MUKESH HARILAL (IN) 2010-03-18 WO disclosed
WO-2010001137-A2 MICROWAVE TORREFACTION OF BIOMASS UNIVERSITY OF YORK (GB) 2010-01-07 WO disclosed
EP-1516010-A1 METHOD FOR THE PRODUCTION OF ESTERS OF POLYALCOHOLS BASF AKTIENGESELLSCHAFT (DE) 2005-03-23 EP disclosed
WO-2003104299-A1 METHOD FOR THE PRODUCTION OF ESTERS OF POLYALCOHOLS BASF AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed
EP-0975224-A1 PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS MONSANTO COMPANY (US) 2000-02-02 EP disclosed
WO-1998033385-A1 PROCESS AND COMPOSITIONS FOR ENHANCING RELIABILITY OF EXOGENOUS CHEMICAL SUBSTANCES APPLIED TO PLANTS MONSANTO COMPANY (US) 1998-08-06 WO disclosed
EP-0376689-A2 Polymeric films of metalloporphyrins as conductive materials for electrocatalysis IDAHO RESEARCH FOUNDATION, INC. (US) 1990-07-04 EP disclosed
EP-0034326-A1 Chiral polysiloxanes, process for their preparation and their use Bayer, Ernst, Prof. Dr. (DE) 1981-08-26 EP disclosed